Re: Gout and risk of Parkinson disease: a prospective study.
Schlesinger
Ilana
I
Schlesinger
Naomi
N
D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D016166:Free Radical Scavengers / Q000378:metabolism; D006073:Gout / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D006074:Gout Suppressants / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D009410:Nerve Degeneration / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control*; D012307:Risk Factors; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D014527:Uric Acid / Q000037:antagonists & inhibitors / Q000097:blood
D016166:Free Radical Scavengers; D006074:Gout Suppressants; D018696:Neuroprotective Agents; D014527:Uric Acid